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Abstract
In our continuing search for camptothecin (CPT)-derived antitumor drugs, novel structurally 
diverse PEG-based 20(S)-CPT sulfonylamidine derivatives were designed, synthesized via a Cu-
multicomponent reaction (MCR), and evaluated for cytotoxicity against four human tumor cell 
lines (A-549, MDA-MB-231, KB, and KBvin). All of the derivatives showed promising in vitro 
cytotoxic activity against the tested tumor cell lines, and were more potent than irinotecan. 
Significantly, these derivatives exhibited comparable cytotoxicity against KBvin, while irinotecan 
was less active against this cell line. With a concise efficient synthesis and potent cytotoxic 
profiles, especially significant activity towards KBvin, these compounds merit further 
development as a new generation of CPT-derived PEG-conjugated drug candidates.
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Multicomponent reactions (MCRs) have received great attention in combinatorial and 
medicinal chemistry because of their ability to generate diverse molecules economically in 
simple one-pot reactions.1,2 Especially, the marriage of MCRs and combinatorial synthesis 
has innovated medicinal chemistry by boosting diversification of organic molecules to 
discover new drug candidates.3,4 Meanwhile, MCRs have recently been introduced into 
macromolecular science. Highly efficient MCRs, such as the Passerini, Kabachnik–Fields, 
and Cu-catalyzed three-component reactions, have been employed to prepare condensed 
polymers, while the multiple reactants of MCRs provide new functionalities to polymer 
main chains.5–13 Compared with the conventional step-by-step or post-modification 
approaches based on two component reactions, this conceptually new strategy offers a 
simple way to prepare functional polymers and greatly enriches the variety of functional 
polymers (both main chains and side groups). Despite fruitful possibilities of MCRs in 
polymer chemistry, the application of polymer-based MCRs in drug-conjugation has not yet 
been described in the literature, and more importantly, the use of MCRs for PEG-based 
camptothecin drugs as described in this communication is a completely new approach in the 
area of polymer-conjugated drugs.
Camptothecin (1, Figure 1) is a cytotoxic natural alkaloid with topoisomerase I inhibitory 
activity. However, therapeutic use of unmodified 1 is hindered by its very low solubility in 
aqueous media, high toxicity, and rapid inactivation through lactone ring hydrolysis in vivo. 
Lactone hydrolysis, which is reversible in acidic media, leads to a water soluble carboxylate. 
In addition, the carboxylate form readily binds to human serum albumin, making it less 
accessible for cellular uptake. This behavior gives rise to a drop in therapeutic efficacy, 
along with formulation difficulties.14–17 To improve the therapeutic potential of 1 (i.e., 
reduce toxicity and improve antitumor activity), polymeric conjugation,18,19 including 
poly(ethylene glycol) (PEG),20,21 cyclodextrin copolymer,22 poly(L-glutamic acid),23 and 
phthalimide polymer,24 have been investigated. Among the many biocompatible polymers, 
the PEG carrier system has well documented properties regarding water solubility, 
biocompatibility, and low immunogenicity, and has been granted FDA approval for human 
usage.25–27 Accordingly, PEGylation can effectively improve the disadvantages of 1, 
including increasing water solubility and lactone stabilization.28,29 For example, linear PEG 
conjugation, as well as elegant architectures such as “bow-tie” dendrimers, has led to 1-
polymer therapeutic drugs and clinical candidates such as prothecan (2, Figure 1),30,31 
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which display increased water solubility, reduced side effects, and enhanced specificity due 
to the action of the enhanced permeability and retention (EPR) effect.
Inspired by the promising results applying CuMCR in macromolecular chemistry, in 
connection with an ongoing investigation of sulfonylamidine-derived antitumor agents, we 
successfully synthesized a large variety of 20-sulfonylamidine camptothecin derivatives.32 
Among them, some new compounds displayed potent antitumor activity with significantly 
different drug-resistance profiles from those of irinotecan (3, Figure 1), a clinically available 
anticancer drug. In addition, they also were effective in drug-sensitive and drug-resistant 
xenograft models at lower doses than 3, demonstrating potential as drug candidates for 
anticancer chemotherapy. These encouraging results prompted us to further extend our 
investigation by exploring the three-component coupling reaction of alkyne, sulfonyl azides, 
and amines as reactants to prepare versatile PEG-based 1-sulfonylamidine derivatives. In 
this study, we describe our design and synthesis of structurally diverse PEG-based 20(S)-1-
sulfonylamidine derivatives via CuMCR and their cytotoxic activity.
As outlined in Scheme 1, various Boc-amino acids were initially added to the 20-hydroxyl 
group of 1 using a diisopropylcarbodiimide (DIPC) coupling reaction. Without isolation, the 
intermediate (4) was further reacted with trifluoracetic acid (TFA) in CH2Cl2 to give the key 
precursor TFA salts (5).33 Subsequently, these key precursors were successfully employed 
as efficient reacting partners in a Cu-catalyzed three-component reaction with sulfonyl 
azides and PEG-alkynes to produce the corresponding target compounds 6–32 in moderate 
yields. In contrast to our previous study, under the optimized conditions, a wide range of 
sulfonyl azide counterparts, including aliphatic, aryl, and heterocyclic types, were all 
efficiently coupled to furnish the corresponding amidines. Moreover, various types of 
alkynes were likewise incorporated with almost the same efficiency. The coupling reaction 
has a wide substrate scope, a high tolerance to various functional groups, and very mild 
reaction conditions. All newly synthesized compounds were purified by column 
chromatography and their structures were confirmed by 1H-NMR and 13C-NMR analysis.
Target compounds 6–32 were evaluated for cytotoxicity against four human tumor cell lines, 
A-549 (lung carcinoma), MDA-MB-231 (triple-negative breast cancer), KB 
(nasopharyngeal carcinoma), and KBvin (MDR KB subline), using a sulforhodamine B 
colorimetric (SRB) assay with triplicate experiments.34 The positive controls were 1 and 3, 
and the screening results are shown in Table 1.
As illustrated in Table 1, all new compounds exhibited significant in vitro cytotoxic activity 
against the four tested tumor cell lines, with IC50 values ranging from 0.0623 to 0.9784 μM, 
and were more active than 3, a clinically used CPT-derived chemotherapeutic drug. 
Remarkably, the new compounds exhibited comparable cytotoxicity against the parental KB 
cell line and MDR KB subline KBvin, while 3 was inactive against KBvin. The encouraging 
results suggested that these new derivatives could overcome the MDR phenotype 
overexpressing P-glycoprotein. In general, the IC50 values also revealed that the A-549 cell 
line was more sensitive than the other three cell lines to these compounds, which is 
consistent with the clinical behavior of other CPT derivatives. Notably, the four most 
promising compounds 15, 24, 27 and 31 showed broad in vitro antitumor spectra and were 
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about 10- to 150-fold more potent than 3. Furthermore, similar to our previous results,32 the 
cytotoxic potencies of these derivatives were dual controlled by altering the length of the 
sulfonylamidine arm as well as the size of the substituent group. The best antiproliferative 
activity was achieved only with an appropriate balance between flexibility and size, such as 
in 15, 24, 27, and 31.
In summary, application of PEG-conjugated drugs has become increasingly frequent in 
medicinal chemistry studies during recent years. Compared with the conventional step-by-
step PEG-modification approaches based on two component reactions, this MCR strategy 
offers a simple way to prepare functional polymers and greatly enriches the variety of PEG-
based 1-related drugs. As an extension to our studies on 1-derived antitumor drugs, we 
designed and synthesized a series of novel PEG-based 20(S)-1 sulfonylamidine derivatives 
via CuMCR, which were then evaluated for antiproliferative activities against four tumor 
cell lines (A-549, MDA-MB-231, KB, and KBvin) by using a sulforhodamine B 
colorimetric assay. All synthesized compounds were more potent than 3 in the cytotoxicity 
assays. Significantly, the new compounds exhibited comparable cytotoxicity against the 
parental KB cell line and MDR KB subline KBvin, while 3 was inactive against KBvin. 
SAR analysis indicated that the size, electron density, and distribution of the substituents 
within the sulfonylamidine side chain are critical to the derivatives’ activity. These findings 
support our further optimization of 1 to develop potential 1-derived anticancer drug 
candidates. Continuing studies to substantiate and improve activity profiles are underway in 
our laboratory and will be reported in due course.
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Structures of camptothecin derivatives
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General synthetic procedure for target compounds 6–32.
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Table 1
Cytotoxicity results against four tumor cell lines.
compound
IC50 (μM)
A-549 MDA-MB-231 KB KBvin
6 0.1065 ± 0.0019 0.5331 ± 0.0081 0.5750 ± 0.0214 0.1260 ± 0.0263
7 0.5047 ± 0.0071 0.6809 ± 0.0158 0.6849 ± 0.0155 0.4335 ± 0.1168
8 0.6728 ± 0.0091 0.9784 ± 0.0059 0.9115 ± 0.0222 0.8714 ± 0.0520
9 0.1098 ± 0.0052 0.5004 ± 0.0199 0.5387 ± 0.0062 0.1277 ± 0.0064
10 0.0841± 0.0023 0.3319 ± 0.0117 0.1670 ± 0.0044 0.1124 ± 0.0161
11 0.1032 ± 0.0056 0.4248 ± 0.0139 0.4622 ± 0.0156 0.1179 ± 0.0024
12 0.1748 ± 0.0122 0.4580 ± 0.0143 0.3959 ± 0.0769 0.1055 ± 0.0044
13 0.0766 ± 0.0459 0.3992 ± 0.2238 0.1278 ± 0.0593 0.1099 ± 0.0073
14 0.1039 ± 0.0023 0.4427 ± 0.0470 0.3408 ± 0.0571 0.3029 ± 0.2155
15 0.0637 ± 0.0146 0.2705 ± 0.1891 0.1283 ± 0.0678 0.0955 ± 0.0295
16 0.0806 ± 0.0013 0.1921 ± 0.0134 0.1390 ± 0.0614 0.0996 ± 0.0049
17 0.0803 ± 0.0218 0.3432 ± 0.1853 0.3223 ± 0.2861 0.2227 ± 0.1677
18 0.0837 ± 0.0024 0.1756 ± 0.0412 0.1042 ± 0.0141 0.0884 ± 0.0038
19 0.1194 ± 0.0037 0.3025 ± 0.0159 0.4943 ± 0.0446 0.1355 ± 0.0018
20 0.0992 ± 0.0297 0.4468 ± 0.2307 0.3262 ± 0.2713 0.1176 ± 0.0203
21 0.1290 ± 0.0603 0.6625 ± 0.0081 0.5592 ± 0.1508 0.2702 ± 0.1207
22 0.0969 ± 0.0003 0.1781 ± 0.0093 0.1396 ± 0.0139 0.1007 ± 0.0049
23 0.0886 ± 0.0283 0.1899 ± 0.0031 0.1491 ± 0.0557 0.1026 ± 0.0156
24 0.0654 ± 0.0238 0.1391 ± 0.0229 0.0873 ± 0.0192 0.1039 ± 0.0292
25 0.4864 ± 0.0102 0.6033 ± 0.0025 0.5941 ± 0.0122 0.3556 ± 0.0350
26 0.1117 ± 0.0359 0.3810 ± 0.1858 0.3503 ± 0.2528 0.2495 ± 0.1561
27 0.0642 ± 0.0265 0.1393 ± 0.0035 0.0998 ± 0.0320 0.0996 ± 0.0284
28 0.3120 ± 0.2834 0.7377 ± 0.0309 0.5782 ± 0.1777 0.4226 ± 0.2258
29 0.2586 ± 0.2508 0.5842 ± 0.0246 0.4598 ± 0.1659 0.3315 ± 0.1568
30 0.1960 ± 0.1539 0.5850 ± 0.0969 0.4347 ± 0.2726 0.3257 ± 0.1703
31 0.0623 ± 0.0195 0.1143 ± 0.0215 0.0803 ± 0.0281 0.0862 ± 0.0279
32 0.4746 ± 0.0013 0.6238 ± 0.0203 0.5885 ± 0.0376 0.3359 ± 0.0011
1 0.0086 ± 0.0007 0.3066 ± 0.1180 0.0500 ± 0.0097 0.0157 ± 0.0011
3 9.480 ± 0.106 14.2820 ± 4.3003 9.828 ± 0.481 >20
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